XORTX Therapeutics (XRTX) Cash from Operations (2022)

XORTX Therapeutics' (XRTX) quarterly Cash from Operations came in at 13838770.24 in Q4 2022, down 1554.36% on a QoQ basis from 951535.92 in Q3 2022.

XORTX Therapeutics (XRTX) Cash from Operations (2022) Analysis & Trends

XORTX Therapeutics (XRTX) has 1 years of Cash from Operations data on file, last reported at 13838770.24 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Ops. (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	1.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	813.00 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-526.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	462.82 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	326.72 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-88.83 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	728.46 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	360.27 Mn
10	XORTX Therapeutics	2.78 Mn	2.78 Mn	-	-

Download Data